Business Insider9d
Novartis’ Ianalumab granted FDA orphan designation
Novartis (NVS)’ Ianalumab, for the treatment of primary immune thrombocytopenia, was granted FDA orphan designation, according to a post on the agency’s website. Published first on TheFly ...
The Boston Globe11d
Novartis acquires local cardiovascular drugmaker Anthos for $925 million
Swiss pharmaceutical giant Novartis announced on Tuesday the purchase of Cambridge-based biopharma firm Anthos Therapeutics for $925 million upfront. The deal, which is expected to close in the ...
Business Insider10d
Novartis initiated with an Underweight at Morgan Stanley
Morgan Stanley analyst Thibault Boutherin initiated coverage of Novartis (NVS) with an Underweight rating and CHF 91 price target The company has a solid outlook but limited earnings upside aside ...
MedCity News12d
Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots
Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer ...
Wall Street Journal11d
Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion
Novartis NOVN0.30%increase; green up pointing triangle agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal ...
FiercePharma25d
Novartis' first Super Bowl ad aims to 'create a movement' with breast cancer awareness blitz
To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s biggest stages. The drugmaker’s first-ever Super Bowl ad is set to ...
Ad Age26d
Novartis will make its Super Bowl debut with a breast cancer awareness ad
Are you a print subscriber? Activate your account. By Tim Nudd - 19 hours 17 min ago By Amir Farhang - 19 hours 17 min ago By Ashley Joseph - 1 day 17 hours ago By Ad Age Staff - 1 day 17 hours ...
pharmaphorum4d
A history of Novartis
Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...
Hosted on MSN11d
Novartis buys Blackstone's Anthos for up to $3.1 billion
(Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...
Business Wire11d
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI ...
pharmaphorum2d
Novartis cues up filings for remibrutinib in chronic hives
Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...